BindRen colestilan regulatory update

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said in a preliminary benefit assessment that BindRen colestilan from Mitsubishi is worse than sevelamer to treat hyperphosphatemia in patients with stage 5 chronic kidney disease (CKD) receiving hemodialysis or peritoneal dialysis for whom a calcium- or aluminum-containing phosphate binder is contraindicated. IQWiG said BindRen has "no additional benefit" vs. calcium- or aluminum-containing phosphate binders because Mitsubishi did not submit "relevant" data. ...